Ralph A Neumüller
3PUBLICATIONS
32CO-AUTHORS
Get your video featured.
Publish with JoVEGet your video featured.
Publish with JoVE
Publications (3)
Sort by Publication Date:
|Sep 09, 2024
Zongertinib (BI 1810631), an Irreversible HER2 TKI, Spares EGFR Signaling and Improves Therapeutic Response in Preclinical Models and Patients with HER2-Driven Cancers.Birgit Wilding, Lydia Woelflingseder, Anke Baum
|Aug 08, 2023
Precision RNAi using synthetic shRNAmir target sites.Thomas Hoffmann, Alexandra Hörmann, Maja Corcokovic
|Jul 26, 2022
Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling.Birgit Wilding, Dirk Scharn, Dietrich Böse
Pageof 1
Frequent Collaborators
2 joint publications
Birgit Wilding
2 joint publications
Daniel Gerlach
2 joint publications
Johannes Zuber
2 joint publications
Flavio Solca
1 joint publications
Gerd Bader
1 joint publications
Harald Engelhardt
1 joint publications
Thomas Hoffmann
1 joint publications
Jakub Zmajkovic
1 joint publications
Matthias Hinterndorfer
1 joint publications
Anna Köferle
